Clinical efficacy of Anterior Path approach and SuperPath approach in total hip Joint replacement: a prospective randomized controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073970

Enrollment

Unknown

Registered

2023-07-26

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

total hip arthroplasty

Interventions

Anterior Path group:Anterior Path approach

SuperPath group:SuperPath approach

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients are diagnosed as ischemic necrosis of femoral head, hip osteoarthritis or femoral neck fracture and confirmed by imaging methods; 2) all patients received THA for the first time; 3) only unilateral THA cases were included; 4) patients with BMI = 35 kg/m2; 5) Patients who have the ability to complete the planned 12-month follow-up.

Exclusion criteria

Exclusion criteria: 1) patients with BMI>35 kg/m2; 2) patients who had received THA before; 3) patients with inflammatory hip diseases or acetabular dysplasia; 4) patients with severe osteoporotic acetabular fractures requiring cemented prosthesis; 5) patients with general contraindications such as severe cardiovascular, liver or renal diseases.

Design outcomes

Primary

Measure	Time frame
Harris Hip Score;	—

Secondary

Measure	Time frame
visual analogue scale;Operation time;Intraoperative blood loss;hidden hemorrhage;Incision length;Drainage volume;Serum markers;Prosthesis position;complications;	—

Countries

China

Contacts

Public ContactWeiping Ji

The People's Hospital of Lishui

2276085@vip.sina.com+86 139 0588 8686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026